BIO KEY INTERNATIONAL INC (BKYI): Nasdaq/NYSE listing notice — BIO-key Q1 rev $1.6M, net loss widens; Nasdaq bid price deficiency notice

BIO KEY INTERNATIONAL INC

Q1 2025 revenue $1.6M (-25% YoY); net loss $736k vs $510k; EPS ($0.16) vs ($0.32).
Cash and equivalents $3.1M at Mar 31, up from $438k at Dec 31, on warrant exercises.
Nasdaq notice on May 9: bid price below $1.00 for 30 days; compliance deadline Nov 5, 2025.
Gross margin 82.6%; SG&A down 23% YoY to $1.37M; operating expenses reduced 18%.
New partnerships: Arrow ECS Iberia, California Ed Tech JPA; deployed PortalGuard for National Bank of Egypt (30k users).

item 2.02 item 3.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

BIO KEY INTERNATIONAL INC received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

May 9, 2025, the Company received notice from the staff of The Nasdaq Stock Market, LLC (“Nasdaq”) stating that the Company’s closing bid price for the last 30 consecutive business days was less than $1.00 per share. As a result, the Company does not satisfy the continued listing requirement to maintain a minimum bid price of $1.00 per share, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). The notification had no immediate effect on the listing or trading of the common stock on the Nasdaq Capital Market. Nasdaq Listing Rule 5810(c)(3)(A) provides a compliance period of 1

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

BIO KEY INTERNATIONAL INC filing history →

Source: SEC EDGAR

accession 0001437749-25-017237

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.